Minimizing risk and maximizing care in metastatic breast cancer: A deep dive into ADC safety
touchEXPERT FOCUS for touchONCOLOGY
Dr. Sara Tolaney, a leading breast medical oncologist, shares insights into the distinct toxicity profiles of antibody–drug conjugates (ADCs) approved for metastatic breast cancer (mBC). She explores practical approaches for monitoring, recognizing, and diagnosing ADC-related side effects, and discusses evidence-based strategies for managing treatment-related toxicities. She also provides guidance to support timely intervention to optimize the care of patients with mBC receiving ADCs.
The experts
Dr. Sara Tolaney, Dana-Farber Cancer Institute and Harvard…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.